About Xintong Medicine
Xintong Medicine is a Healthcare company based in Xi'an (China) founded in 2000. Drugs for treating infectious and liver diseases are developed. Xintong Medicine has raised $14.61 million across 2 funding rounds from investors including Beituo Capital. Xintong Medicine has completed 1 acquisition, including Chiva Pharmaceuticals. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral.
Company details
Xintong Medicine was founded in 2000 in Xi An, China, within the pharmaceutical sector. Drugs such as paradefovir mesylate and hepunovvir are developed for anti-hepatitis B treatment, while MB07133 targets liver cancer using prodrug technology. Captisol, a cyclodextrin excipient, is provided for injections to enhance drugs like CE-phosphophenytoin sodium and CE-menoxicam. Generic drugs including BEBT908, BEBT206, Telmisartan, and Rabeprazole are also produced for various diseases.
- Headquarters Xi'an, China
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website xtyw.com.cn
- Total Equity Funding$14.61M (USD)
in 2 rounds
- Latest Funding Round$14.61M (USD), Series C
Sep 2020
- Investors
- Investments & Acquisitions
Funding Insights of Xintong Medicine
Xintong Medicine has successfully raised a total of $14.61M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $14.61 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.61M
- Total Rounds 2
- Last Round Series C — $14.61M
- Investors Count 1
All 2 funding rounds of Xintong Medicine with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $14.61M | Series C | – | Beituo Capital | – |
| Jun 2018 | Series B | – | Beituo Capital | – |
1 investors in total: 1 institutional.
Investors in Xintong Medicine
Xintong Medicine has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Beituo Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Boutique investment banking firm | 2013 | northbeta.com | Beijing, China |
Investor details for Xintong Medicine
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Xintong Medicine
Xintong Medicine has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Chiva Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Innovator drugs are co-developed and commercialized between US and China. | chivapharma.com | Los Altos Hills, United States | 2010 | Jun 2012 | •••• |
Complete acquisition details for Xintong Medicine
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Xintong Medicine
4 dated milestones of Xintong Medicine across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Xintong Medicine is founded.
- Acquisition Acquires Chiva Pharmaceuticals.
- Funding First funding round.
- Funding Latest funding round, Series C, of $14.6M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Xintong Medicine
Complete news archive for Xintong Medicine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xintong Medicine
Xintong Medicine was founded in 2000 and raised its 1st funding round 18 years after it was founded.
Xintong Medicine is headquartered in Xi'an, China. It is registered at Xi'an, Shaanxi, China.
Xintong Medicine is a funded company, having raised a total of $14.61M across 2 funding rounds to date.
Xintong Medicine was founded in 2000 in Xi An, China, within the pharmaceutical sector. Drugs such as paradefovir mesylate and hepunovvir are developed for anti-hepatitis B treatment, while MB07133 targets liver cancer using prodrug technology. Captisol, a cyclodextrin excipient, is provided for injections to enhance drugs like CE-phosphophenytoin sodium and CE-menoxicam. Generic drugs including BEBT908, BEBT206, Telmisartan, and Rabeprazole are also produced for various diseases.
Xintong Medicine has made 1 acquisition, including Chiva Pharmaceuticals.
Xintong Medicine has 1 investor. Key investors include Beituo Capital.